TBPH — Theravance Biopharma Share News
0.000.00%
Last trade - 00:00- $857.84m
- $495.97m
- $107.46m
Ireland's Theravance Biopharma Q4 revenue misses expectations
Corrected: BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million
U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group
U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy
Theravance falls as co weighs options including possible sale after drug trial failure
NASDAQ RESUMED AT 09:00 AM
Theravance plans strategic review, including possible sale, after drug trial failure (updated)
Theravance Biopharma's blood pressure drug fails to meet main goal in late-stage trial
Brief: Theravance Biopharma Reports Phase 3 Cypress Study Did Not Meet Primary Endpoint Board Accelerates Strategic Review And Announces Cost Reduction Actions
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:26 AM
Theravance Biopharma marginally beats Q3 revenue estimates, YUPELRI sales up 15%
Brief: Theravance Biopharma Q3 Operating Income USD -6.455 Million
Brief: Theravance Biopharma Inc - Co And Mylan Settle With Cipla Over Yupelri Inhalation Solution - SEC Filing
Theravance Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Theravance Biopharma Q2 Operating Income USD -2.725 Million
Theravance Biopharma Inc expected to post earnings of 67 cents a share - Earnings Preview
Brief: Theravance Biopharma Announces Approval Of Yupelri By China's NMPA
Brief: Theravance Biopharma - Theravance And Mylan Enter Settlement Agreement With Eugia - SEC Filing
Brief: Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million